Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm focused on hematologic malignancies, announced that CEO John A. Scarlett will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 12:35 p.m. ET. The event will be webcasted through the Investor Relations section on Geron's website and will be available for replay for 30 days post-event. Geron is currently advancing two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005004/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What is the participation of Geron Corporation's CEO in the Wedbush PacGrow Healthcare Virtual Conference?

Geron Corporation's CEO, John A. Scarlett, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35 p.m. ET.

How can I watch the webcast of Geron Corporation's presentation at the conference?

The webcast of the presentation will be available through the Investor Relations section of Geron's website and will be archived for 30 days.

What clinical trials is Geron Corporation currently conducting?

Geron Corporation is conducting two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

What is the focus of Geron Corporation's research and development?

Geron Corporation focuses on developing a first-in-class telomerase inhibitor, imetelstat, for treating hematologic malignancies.

When will the Geron Corporation's presentation at the Wedbush Conference be available for replay?

The presentation will be available for replay for a period of 30 days following the live event on August 10, 2022.